The role of fetal inherited thrombophilia in development of various forms of fetal growth restriction syndrome

Роль фетальных наследственных тромбофилий в развитии различных форм синдрома задержки роста плода
Nikolay Scherbina 1, Mikhail Makarenko 2, Iryna Kuzmina 1
More Detail
1 № 1 Kharkov national medical university, Kharkov, Ukraine
2 Municipal specialized maternity hospital Kyiv, Kyiv, Ukraine
J CLIN MED KAZ, Volume 4, Issue 34, pp. 49-53.
OPEN ACCESS 3070 Views 2220 Downloads
Download Full Text (PDF)

ABSTRACT

The aim: study significance of fetal thrombophilias (FT) in development of different forms of fetal growth restriction syndrome (FGRS).
Methods: The method of polymerase chain reactions was conducted to analyze blood from umbilical cord for FT of 77 new-born children with symmetric form (25 newborns - 1st group), and asymmetric form (52 – 2nd group) of SGIF and at 30 healthy new-borns (control group). Analysis of inherited fetal thrombophilia included: polymorphism of factor of V Leiden, determination of mutation of gene of folate dependent enzyme of methylene-tetra-hydrofolate reductase MTHFR С677Т, polymorphism «4 G/5G» in the gene of inhibitor of activator of plasminogen I type of PAI - I, polymorphism of «I/D» in the gene of tissue activator of plasminogen, polymorphism in the gene of Hageman’s factor FHag «46С/Т », polymorphism of «- 455G/A» in the gene of Fibrinogenum, and also mutation in the gene of prothrombin of G20210A and multigene form of thrombophilias.
Results: The fetal inherited thrombophilias identified in the different forms of SGIF. Frequency of their discovery of the symmetric form of SGIF substantially higher in comparison to the asymmetric form of FGRS. Combination of a few mutations predominates among the studied forms of FGRS. Fetal thrombophilias are important differentially-diagnostic signs of development of various forms of FGRS.
Conclusion: Research of fetal thrombophilias allows to use them as markers of development of one or another form of FGRS and confirm genetic nature of development of symmetric form of FGRS.
Keywords: fetal thrombophilias, Fetal Growth Restriction Syndrome

CITATION

Scherbina N, Makarenko M, Kuzmina I. The role of fetal inherited thrombophilia in development of various forms of fetal growth restriction syndrome. Journal of Clinical Medicine of Kazakhstan. 2014;4(34):49-53.

REFERENCES

  • Strizhakov A.N., Timohina E.V. Sindrom zaderzhki rosta ploda: sovremennye predstavlenija o patogeneze i akusherskoj taktike (Fetal growth retardation: current concepts of pathogenesis and obstetric tactics), Materialy V Ezhegodnogo kongressa specialistov perinatal’noj mediciny “Sovremennaja perinatologija: organizacija, tehnologija i kachestvo”, Moskva, Rossija, 2010, pp.78-80.
  • Kuz’mina I.Ju. Vlijanie povrezhdajushhih perinatal’nyh faktorov na sostojanie novorozhdennyh pri sindrome vnutriutrobnoj zaderzhki rosta ploda (Damaging influence of perinatal factors on newborns with the syndrome of intrauterine growth retardation),Vestnik Har’kovskogo nacional’nogo universiteta imeni V.N. Karazina, 2000, No.12 (720), pp.56-58.
  • Timohina E.V. Patogeneticheskie mehanizmy razvitija sindroma zaderzhki rosta ploda i problemy lechenija (Pathogenetic mechanisms of fetal growth retardation and problems of treatment), Voprosy ginekologii, akusherstva i perinatologii, 2012, No.2(11), pp.17-20
  • Salomon O., Seligsohn U., Steinberg D.M. et al.The common prothrombotic factors in nulliparous women do not compromise blood flow in the feto-maternal circulation and are not associated with preeclampsia or intrauterine growth restriction, American journal Obstetric and gynecology, 2005, No. 6(193), pp.2180-2181.
  • Pjurbeeva E. N. Kliniko-patogeneticheskaja znachimost’ vrozhdennoj trombofilii v razvitii zaderzhki vnutriutrobnogo razvitija ploda (Clinico-pathogenetic significance of congenital thrombophilia in the development of intrauterine growth retardation): avtoref. diss. kand. med. nauk, S-Pb, 2008, 23 p.
  • Hoffman R., Brenner B. Thrombophilia related issues in women and children, Semin. Thromb. Hemost, 2005, No.1(31), pp.97- 103.
  • Serov V.N., Pasman N.M., Sturov V.G., Drobinskaja A.N. Trombofilii v praktike vracha akushera-ginekologa (Klinicheskoe znachenie, diagnostika, taktika, metody terapii) (Thrombophilia in practice obstetrician-gynecologist (clinical significance, diagnosis, tactics, methods of therapy)). Metodicheskie rekomendacii, Novosibirsk,ID Sova, 2007, 88p.
  • Kvarachelija E.E. Klinicheskoe znachenie vyjavlenija geneticheskoj i priobretennoj trombofilii pri vedenii beremennyh s gipertenzivnym sindromom (The clinical significance of detection of genetic and acquired thrombophilia in the management of pregnant women with hypertensive syndrome): avtoref. diss. kand. med. nauk, Moskva, Rossija, 2007, 23 p.
  • Bajmuradova S. M. Patogenez, principy diagnostiki i terapii sindroma poteri ploda, obuslovlennogo priobretennymi i geneticheskimi defektami gemostaza (Pathogenesis, principles of diagnosis and therapy of fetal loss syndrome caused by genetic defects and acquired hemostatic): avtoref. diss. dokt. med. nauk, Moskva, Rossija, 2007, 46 p.
  • Makacarija A.D., Bicadze V.O., Akin’shina S.V.Trombozy i trombojembolii v akushersko-ginekologicheskoj klinike. Molekuljarnogeneticheskie mehanizmy i strategija profilaktiki trombojembolicheskih oslozhnenij (Thrombosis and thromboembolism in obstetric clinic. Molecular genetic mechanisms and strategies for prevention of thromboembolic complications), Rukovodstvo dlja vrachej,M.: MIA, 2007, 1064 p.
  • Erez О., Romero R., Espinoza J. [et al.]. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age, J Matern Fetal Neonatal Med, 2008, No.21(5), pp. 279-287.
  • Kutteh W.H., Triplett D.A. Thrombophilias and recurrent pregnancy loss, Semin Reprod Med, 2006, No.1(24), pp.54-66.
  • Martinez Zamora M. A. et al. Thrombin activatable fibrinolysis inhibitor and clot lysis time in pregnant patients with antiphospholipid syndrome: relationship with pregnancy outcome and thrombosis, American Journal of Reproductive Immunology, 2009, Т. 62, No. 6, pp. 381-389.
  • Martínez-Zamora, M., et al. “Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome, Fertility and sterility, (2010): T.94,No.6, pp.2437-2440.